CLL Society ASH 2021 Highlights from Day 2 of ASH 2021! Dr. Brian Koffman gives up updates

[bkoffman]

ASH 2021 Highlights from Day 2 of ASH 2021! Dr. Brian Koffman gives up updates on the reversible non-covalently binding BTKi (Bruton’s tyrosine kinase inhibitor) pirtobrutinib (formerly LOXO-305), another reversable BTKi known as MK-1026 (formerly ARQ-531), 3-year follow-up data from the Ascend Trial: Acalabrutinib vs Rituximab plus Idelalisib or Bendamustine in Relapsed/Refractory CLL, as well as a study analyzing of the impact of del 17p and TP53 mutations on therapy outcomes with various agents, and much more! cllsociety.org/2021/12/ash-...

[Ernest2]

Big thanks Brian for interpreting all those presentations for us, and a very big well done on the twelve years.

Best wishes,

Ernest

[Hm15]

Thank you very much for listing these and explaining what they mean. Do you know if any of the time limited treatment programmes using novel agents suggest there is any possibility of recovery of the immune system?Thanks

[bennevisplace]

A great summary again, thanks Brian

[bkoffman CLL CURE Hero]

None seen yet.